BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ozawa M, Ohtani H, Komatsuda A, Wakui H, Takahashi N. VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience. Clin Exp Nephrol 2021. [PMID: 34115234 DOI: 10.1007/s10157-021-02090-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 . Multiple drugs. Reactions Weekly 2022;1924:299-299. [DOI: 10.1007/s40278-022-23652-9] [Reference Citation Analysis]
2 Miao C, Zhu X, Wei X, Long M, Jiang L, Li C, Jin D, Du Y. Pro- and anti-fibrotic effects of vascular endothelial growth factor in chronic kidney diseases. Ren Fail 2022;44:881-92. [PMID: 35618410 DOI: 10.1080/0886022X.2022.2079528] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yoshimura Y, Sawa N, Matsuoka S, Ikuma D, Oba Y, Sekine A, Hasegawa E, Mizuno H, Yamanouchi M, Suwabe T, Hoshino J, Kono K, Kinowaki K, Ohashi K, Toda S, Matoba S, Wakui H, Ubara Y. Glomerular Microangiopathy with Cellular Crescent-like Formation and Endotheliopathy Due to Ramucirumab Treatment for Metastatic Sigmoid Colon Cancer: A Case Report. Intern Med 2022. [PMID: 35569979 DOI: 10.2169/internalmedicine.9185-21] [Reference Citation Analysis]
4 Mori K. Determinants of the Pathological Features of Renal Adverse Effects Due to Vascular Endothelial Growth Factor Signaling Inhibition. Intern Med 2022. [PMID: 35569974 DOI: 10.2169/internalmedicine.0044-22] [Reference Citation Analysis]